PCM
BMRN icon

Prelude Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Prelude Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,100
Closed -$834K – 1489
2015
Q2 		$834K Buy
6,100
+100
+2% +$12.4K 0.12% 207
2015
Q1 		$748K Buy
+6,000
New +$636K 0.1% 238

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prelude Capital Management's BMRN Position: Q4 2025 in Review

Prelude Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 5,317 shares — an estimated $288K sold.

Prelude Capital Management first reported a position in BMRN in Q2 2013 and held it in 35 quarters. The position peaked at $1.52M in Q4 2022. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • Prelude Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Prelude Capital Management sold 5,317 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $288K.
  • Prelude Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 35 quarters.
  • Prelude Capital Management's BioMarin Pharmaceuticals position peaked at $1.52M in Q4 2022.
  • 538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.